Introduction
============

Hematopoietic SCT (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ Forecasts predict an on-going increase in HSCT in the near future. The annual activity survey, describing the status of HSCT in Europe, has become an instrument used to observe trends and to monitor changes in technology use.^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ The survey captures the numbers of HSCT performed in the preceding year from each participating team, split by indication, donor type and stem cell source. The standardized structure of the survey over many years and the excellent commitment by the participating teams allows us to observe changes over time and to evaluate factors associated with such changes. More recently, the survey has included information on cellular transplants with hematopoietic stem cells for non-hematopoietic use, as well as on the use of non-hematopoietic stem and progenitor cells.^[@bib11]^ This coincides with the recent interest of the World Health Organization ([www.who.org](http://www.who.org)) in cell and tissue transplants and further stresses the need for adequate and timely information.^[@bib12]^

The European Group for Bone Marrow Transplantation (EBMT) analyses in previous years have shown an increase in the annual absolute HSCT numbers and transplant rates (number of HSCT/10 million inhabitants) of about 4--13% (median 8%) for allogeneic and of 1.5--9.5% (median 4%) for autologous HSCT.

This report is based on the 2011 survey data. In addition to transplant rates and indications, stem cell source and donor type in allogeneic HSCT, we provide data on proportions of transplants done in low, intermediate and high transplanting centers and data on important differences among countries in the use of reduced intensity (RIC) versus myeloablative conditioning and in the use of DLI post transplant for recipients of allogeneic HSCT.

Patients and methods
====================

Data collection and validation
------------------------------

Participating teams were requested to report data for 2011 by indication, stem cell source and donor type as listed in [Table 1](#tbl1){ref-type="table"}. Quality control measures included several independent systems: confirmation of validity of the entered data by the reporting team, selective comparison of the survey data with MED-A data sets in the EBMT Registry database, cross-checking with the National Registries and onsite visits of selected teams.

Teams
-----

A total of 680 centers from 48 countries were contacted for the 2011 survey (39 European and 9 affiliated countries); of which 651 teams from 46 countries (37 European, 9 affiliated countries) reported their numbers. This corresponds to a 96% return rate and includes 537 active EBMT member teams. Fourteen active teams failed to report in 2011 while 15 teams reported no activity due to transplant program development or closure.

Contacted teams are listed in the appendix in alphabetical order by country, city, EBMT center code, with their reported numbers of first and total HSCT and of first allogeneic and autologous HSCT. The WHO regional office definitions ([www.who.org](http://www.who.org)) were used to classify countries as European or Non-European. According to information received, there were no blood or marrow transplants performed in Albania, Andorra, Armenia, Georgia, Liechtenstein, Malta, Moldavia, Monaco, Montenegro and San Marino in 2011. Nine non-European countries participated in the 2011 EBMT survey: Algeria, Iran, Israel, Jordan, Lebanon, Nigeria, Saudi Arabia, South Africa and Tunisia. Their data, 6% of the total data set, are included in all the analyses.

Definitions
-----------

### Patient and transplant numbers

Wherever appropriate, patient numbers corresponding to the number of patients receiving a first transplant and transplant numbers reflecting the total number of transplants performed are listed. Multiple transplants may include multiple transplants defined as subsequent transplants within a planned double or triple autologous or allogeneic transplant protocol, and retransplants (autologous or allogeneic) defined as unplanned HSCT for rejection or relapse after a previous HSCT.

Information on stem cell source includes BM, peripheral blood or cord blood; transplants with more than one source were categorized as cord blood HSCT if cord blood was present or peripheral blood HSCT if BM and peripheral blood were used. Information on use of RIC transplants, as defined by EBMT, was collected.

Information on additional cellular therapies was subdivided into: HSC for non-hematopoietic use; non-hematopoietic stem cell therapies; MSC therapies for rejection or GvHD prevention/treatment; and donor lymphocyte infusions. Collection of information was harmonized with similar surveys carried out by EULAR (European League against Rheumatism; [www.eular.org](http://www.eular.org)) and TERMIS-EU (Tissue Engineering and Regenerative Medicine International Society; [www.termis.org](http://www.termis.org)).^[@bib11]^

Transplant rates
----------------

Transplant rates, defined as numbers of HSCT per 10 million inhabitants, were computed for each country without adjustments for patients who crossed borders and received their HSCT in a foreign country. Population numbers were obtained from the US census bureau database (<http://www.census.gov/population/international/data/idb/rank.php>).

Analysis
--------

Wherever appropriate, absolute numbers of transplanted patients or transplants or transplant rates are shown for specific countries, indications or transplant techniques. Team size was defined as low, intermediate or high based on 1--25, 25--75 and \>75 patients transplanted. Team size was defined separately for autologous and allogeneic HSCT. To estimate the percentage of allogeneic HSCT done using a RIC regimen and the percentage of allogeneic HSCT that are followed by a DLI, the transplant years 2008--2011 were averaged and compared across countries. For this comparison, only countries with \>100 allogeneic HSCT annually were included.

Results
=======

2011 Data
---------

### Participating teams in 2011

Of the 651 teams, 403 (62%) did both allogeneic and autologous transplants; 226 (35%) restricted their activity to autologous HSCT only and 12 teams (2%) to allogeneic transplants only. Ten teams (1%) reported having performed no transplants in 2011. The list of the participating teams can be downloaded as a [Supplementary informaton](#sup1){ref-type="supplementary-material"} file online.

Numbers of patients and transplants
-----------------------------------

A total 32 075 patients were transplanted in 2011. Of these, the first transplant for 13 470 (42%) was allogeneic, while the first transplant for 18 605 (58%) was autologous.

Furthermore, there were 2073 re-transplants (1018 allogeneic/1055 autologous) and 1512 multiple transplants (61 allogeneic/1451 autologous), bringing the total to 35 660 HSCT procedures, 14 549 allogeneic (41%) and 21 111 autologous (59%) performed in 2011, which is an increase of 7% compared with 2010.^[@bib13]^

Indications for HSCT in 2011 are listed in detail in [Table 1](#tbl1){ref-type="table"} and their distribution is illustrated in [Figures 1a and b](#fig1){ref-type="fig"}: allogeneic HSCT and autologous HSCT, respectively. Main indications were lymphoid neoplasias, including non-Hodgkin\'s lymphoma, Hodgkin\'s lymphoma and plasma cell disorders, leukemias, solid tumours and non-malignant disorders. As seen in previous years, the majority of HSCT for lymphoid malignancies were autologous while leukemia is treated more commonly using stem cells from allogeneic donors. Autologous HSCT for non-malignant disorders predominantly include patients with autoimmune disorders.

As compared with the previous year, the total number of transplants increased by 6.9% (9% allogeneic HSCT and 5.5% autologous HSCT). The number of unrelated donor transplants increased by 10% from 7098 to 7799.^[@bib13]^ Areas of important changes in transplant activity were an increase in AML first remission allo HSCT by 14%, and in more advanced disease by 9%, and an increase in myelodysplastic syndrome/secondary AML allogeneic HSCT by 20%. Allogeneic HSCT for CLL increased by 24%, there was a decrease of myeloproliferative neoplasm allogeneic HSCT by 26% and for CML not in chronic phase by 11%. In non-malignant diseases, there was an increase in allogeneic HSCT for aplastic anemia by 19%, for thalassemia by 39%, primary immune deficiencies by 10% and in inherited disorders of metabolism by 33%. For autologous transplants, the main increase could be seen for plasma cell disorders (10%) and non-Hodgkin\'s disorder (3%) while the autoimmune disorders decreased by 20%, but in general, the changes in trends for autologous HSCT were much less dramatic.

Stem cell source and donor type
-------------------------------

There were clear differences in the use of stem cell source between autologous and allogeneic HSCT. Of the 21 111 autologous transplants, 186 (1%) were BM derived and 20 925 (99%) were derived from peripheral blood stem cells or from combined peripheral blood and BM.

Of the 14 549 allogeneic transplants, 3150 (22%) were BM, 10 566 (72%) were peripheral blood and 833 (6%) were cord blood transplants ([Figure 2a](#fig2){ref-type="fig"}). Cord blood was used as the stem cell source for 46 (0.8%) of HLA-identical siblings, 6 (0.6%) from other family members and 781 (10%) of unrelated donors. No autologous cord blood HSCT was reported for 2011. The highest incidence of cord blood transplants from unrelated donors was seen in France, Spain and Italy: 424 (54% of all unrelated cord blood HSCT).

The choice of stem cell source differed by main indication for all types of allogeneic HSCT. BM remained the preferred source of stem cells for allogeneic transplants for non-malignant disorders (57%).

Donors for the 14 549 allogeneic HSCT were HLA-identical siblings (5677 (39%) BM or peripheral blood donors; 46 (0.0.3%) targeted cord blood HSCT), other family members (983; 7%), syngeneic twin donors (44; 0.3%), unrelated BM or peripheral blood donors (7,018; 48%) or unrelated cord blood donors (781; 5%) [Figure 2b](#fig2){ref-type="fig"}). The percentage of unrelated donor HSCT continues to increase and has reached 54% of all allogeneic HSCT in 2011.^[@bib14]^

RIC
---

Numbers of RIC HSCT continued to increase from 1436 in 2000 to 5567 in 2011 ([Figure 3a](#fig3){ref-type="fig"}).^[@bib15]^ RIC conditioning was used for 38% of all allogeneic HSCT, a proportion similar to that of last year\'s survey. In countries performing \>100 allogeneic HSCT per year, the highest percentage of RIC HSCT was seen in the Netherlands (60%). In the United Kingdom, Denmark and France \>50% of allogeneic HSCT were performed using RIC but the percentages vary widely with some countries having \<20% of transplants done with RIC conditioning ([Figure 3b](#fig3){ref-type="fig"}).

Donor lymphocyte infusions
--------------------------

In 1997, 305 patients were reported as having received DLI infusions after transplant; this has increased to 2279 in 2011 and corresponds to 16% of patients with an allogeneic HSCT ([Figure 4a](#fig4){ref-type="fig"}). In countries performing \>100 HSCT per year, the highest percentage of allogeneic HSCT receiving DLI post transplant can be seen in the Netherlands (32%), with a number of countries in which \<5% of transplants are followed by DLI ([Figure 4b](#fig4){ref-type="fig"}).

Additional cellular therapies
-----------------------------

In all, 28 teams from 13 countries reported having treated 281 patients with hematopoietic stem cells for non-hematopoietic use in 2011. The main indications were cardiovascular, 190 (all autologous); neurological, 26 (4 autologous); tissue repair, 55 (50 autologous) and epithelial: 10 (9 autologous). In addition, 330 patients in 71 teams and 16 countries received MSCs for prevention/treatment of GvHD (248), prevention/treatment of graft failure (59) and for unspecified reasons (23).

Transplant rates and team size
------------------------------

Transplant rates differed substantially between participating European countries ([Figure 5a](#fig5){ref-type="fig"}: allogeneic HSCT; [Figure 5b](#fig5){ref-type="fig"}: autologous HSCT). These differences related to all types of HSCT.

Transplant rates per 10 million inhabitants for autologous HSCT vary from 14.2 in Ukraine to 519 in Italy, median 151. Transplant rates for allogeneic HSCT vary from either 0 in several countries or 1.3 in Ukraine to 547 in Israel and 380 in Germany, median 109.

To illustrate the impact of team size, transplant teams were grouped into low (1--25 HSCT) intermediate (25--75) HSCT and high (more than 75 HSCT) teams separately for autologous and allogeneic procedures.

In all, 415 of the 651 teams reporting in 2011 performed an allogeneic HSCT in 2011, 203 teams (49% and 2594 HSCT) reported \<25 transplants, 169 teams (41% and 7219 HSCT); 25--75 HSCT and 43 teams (10% and 4736 HSCT) performed \>75 HSCT in 2011.

Also, 629 of the 651 teams reporting in 2011 performed an autologous HSCT in 2011, 304 teams (48% and 3691 HSCT) reported \<25 transplants, 267 teams (43% and 11 643 HSCT); 25--75 HSCT and 58 teams (9% and 5777 HSCT) performed \>75 HSCT in 2011. Data are shown in [Table 2](#tbl2){ref-type="table"}. It is evident that close to half of the teams fall into the category of low-frequency teams performing \<20% of all transplants, be they autologous or allogeneic HSCTs.

Discussion
==========

The EBMT activity survey has been conducted annually since 1990. The 2010 survey had, for the first time, reported \>30 000 patients transplanted in a given year. This trend continues with an additional increase by 7% in 2011. This 2011 report is on 35 660 transplants.

HSCT continues to increase for some indications but not for others. Of interest is an important growth of allogeneic HSCT for myelodysplastic syndrome, CLL and for non-malignant disorders, in particular marrow failure and inherited disorders of metabolism. Some indications are decreasing, such as allogeneic transplants for myeloproliferative neoplasias. This is possibly due to the development of new drugs such as janus kinase 2 inhibitors. A success of these drugs may result in decreasing needs for transplant in these diseases similar to the effect the development of tyrosine kinase inhibitors (TKI) had on transplant rates for CML. Of interest, CML was the main indication for allogeneic HSCT in the 1990s, and the highest number of allogeneic HSCT for CML was 1396 in 1999, whereas in 2011 the number of transplants had reduced to 391, which corresponds to 1/4 of the activity before tyrosine kinase inhibitor availability.

We show data on the use of RIC for allogeneic HSCT and in the use of DLI after allogeneic HSCT. Of interest is the wide variation in the use of RIC conditioning and of DLI, which varies widely across countries. As we do not know the precise indications for the choice of these interventions, the appropriateness cannot be analyzed. Discrepancies have to be discussed, however, and there appears to be a need for more standardization in the field as differences up to threefold in the use of a given technology must be considered as evidence for uncertainty about appropriate use.

Finally, there is a description of 2011 transplants by team size. It is obviously beyond the scope of this paper to discuss in detail appropriateness of decision by health planners on how transplant units are established, but we have to acknowledge the fact that approximately half of the centers fall into the category of low-frequency centers with \<25 HSCTs in a given category (allogeneic and autologous HSCTs being analyzed separately) and that these low-frequency centers perform \<20% of all HSCTs. In a previous paper by the EBMT activity survey, the relationship between transplant rates and team density have been discussed.^[@bib5]^ The principles of concentrating activity to few centers in order to maintain the highest degrees of team experience and as a consequence better treatment quality, which also needs to be proven, versus the principle of easy access to care, proximity of patients to the nearest transplant center and as a consequence smaller team size, cannot be easily resolved.

Last, in spite of the economic crisis in Europe, there does not appear to be a decrease in transplant activity since 2009 but rather a continued annual increase in the use of HSCT technology.
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![Absolute numbers and relative proportions of indications for an HSCT in Europe in 2011. (**a**) Proportions of disease indications for an allogeneic HSCT in Europe in 2011. (**b**) Proportions of disease indications for an autologous HSCT in Europe in 2011. BMF=bone marrow failure; HD= Hodgkin\'s disease; IDM=inherited disorders of metabolism; MDS=myelodysplastic syndrome; MPS=myeloproliferative syndrome; NHL=non-Hodgkin\'s lymphoma; PCD=plasma cell disroder; PID=primary immunodeficiency.](bmt201351f1){#fig1}

![Donor type and stem cell source in allogeneic HSCT. (**a**) Stem cell source in allogeneic HSCT in 2011. (**b**) Donor type in allogeneic HSCT in 2011. CB=cord blood.](bmt201351f2){#fig2}

![RIC in allogeneic HSCT. (**a**) Absolute numbers of RIC HSCT 2000--2011. (**b**) Percentage of patients receiving RIC HSCT during the years 2007--2011 in countries performing \>100 allogeneic HSCT per year.](bmt201351f3){#fig3}

![DLI in allogeneic HSCT. (**a**) Absolute numbers of patients receiving DLI since 1997. (**b**) Percentage of patients receiving DLI during the years 2007--2011 in countries performing \>100 allogeneic HSCT per year.](bmt201351f4){#fig4}

![Transplant rates in Europe (=total number of HSCT per 10 million inhabitants) by participating country. (**a**) Allogeneic transplant rates per10 million population in 2011. (**b**) Autologous transplant rates per 10 million population in 2011.](bmt201351f5){#fig5}

###### Numbers of hematopoietic SCTs in Europe 2011 by indication, donor type and stem cell source

                                        *HLA-identical sibling*   *Mis-matched relative*   *Unrelated*   *Autologous*   *Total*                                                   
  ------------------------------------- ------------------------- ------------------------ ------------- -------------- --------- --- ------ ------ ----- ----- -------- -------- --------
  Leukemias                             756                       2880                     8             151            312       4   841    4016   503   28    614      9471     642
   AML                                  316                       1417                     4             76             163           302    1897   230   25    482      4405     507
    Early disease                       230                       974                      2             30             80            182    991    120   20    413      2609     433
    Advanced disease                    86                        443                      2             46             83            120    906    110   5     69       1796     74
   ALL                                  283                       585                      3             44             90        3   306    619    164   1     75       2097     76
    Early disease                       179                       403                                    19             38            170    382    78    1     55       1269     56
    Advanced disease                    104                       182                      3             25             52        3   136    237    86          20       828      20
   CML                                  38                        118                                    3              13        1   29     173    16          1        391      1
    Early disease                       23                        42                                     1              7             15     69     6                    163       
    Advanced disease                    15                        76                                     2              6         1   14     104    10          1        228      1
   Myelodysplastic disorders            98                        464                                    20             37            160    866    75    1     13       1720     14
   Myeloproliferative disorders         11                        114                      1             5              2             18     193    10                   354       
   CLL                                  10                        182                                    3              7             26     268    8     1     43       504      44
                                                                                                                                                                                   
  Lymphoproliferative disorders         80                        783                                    54             50            101    1001   66    75    16 223   2135     16 298
   Plasma cell---myeloma                25                        219                                    2              10            29     280    13    15    8326     578      8341
   Plasma cell---other                  2                         10                                                                  1      17     3           245      33       245
   Hodgkin\'s lymphoma                  11                        140                                    31             14            15     134    13    21    2045     358      2066
   Non-Hodgkin\'s lymphoma              42                        414                                    21             26            56     570    37    39    5607     1166     5646
                                                                                                                                                                                   
  Solid tumors                          9                         8                                      1              40            8      5      3     66    1433     74       1499
   Neuroblastoma                        6                         1                                                     23            4      2      3     31    402      39       433
   Soft tissue sarcoma                                            1                                                     7             1      1            4     37       10       41
   Germinal tumors                                                1                                                                                       4     351      1        355
   Breast cancer                                                  1                                                                                             54       1        54
   Ewing                                1                         2                                      1              4             1      2            9     211      11       220
   Other solid tumors                   2                         2                                                     6             2                   18    378      12       396
                                                                                                                                                                                   
  Non-malignant disorders               577                       260                      37            75             107       1   311    187    137   11    127      1692     138
   BM failure---SAA                     200                       130                      3             11             19            128    82     22                   595       
   BM failure---other                   51                        17                       4             6              6             44     24     12                   164       
   Hemoglobinopathies---thalassemia     150                       59                       11            21             24            21     10     5                    301       
   Hemoglobinopathies---other           51                        25                       10            5              4             6      3      2                    106       
   Primary Immune deficiencies          88                        20                       6             26             38        1   75     53     56    6     5        363      11
   Inherited disorders of  Metabolism   34                        7                        3             6              15            32     12     37    4     4        146      8
   Auto immune disease                  3                         2                                                     1             5      3      3     1     118      17       119
                                                                                                                                                                                   
  Others                                28                        10                       1             2              5             14     26     12          28       98       28
                                                                                                                                                                                   
  Total Patients                        1450                      3941                     46            283            514       5   1275   5235   721   180   18 425   13 470   18 605
  Additional transplants                44                        286                                    43             137       1   55     453    60    6     2500     1079     2506
  Total Transplants                     1494                      4227                     46            326            651       6   1330   5688   781   186   20 925   14 549   21 111

Abbreviations: CB=cord blood; PB=peripheral blood; SAA=severe aplastic anemia.

###### Numbers of teams and transplants by size category; low, intermediate and high

  *Team size*     *No. of teams*         *Percentage of total teams*   *No. of HSCT*   *Percentage of total transplants*   *Median (range) HSCT per team*   
  --------------- ---------------------- ----------------------------- --------------- ----------------------------------- -------------------------------- --------------
  *Allogeneic*                                                                                                                                              
   Low            \<25 HSCT per team     203                           49              2594                                18                               13 (1--25)
   Intermediate   25--75 HSCT per team   169                           41              7219                                49                               40 (26--74)
   High           \>75 HSCT per team     43                            10              4736                                33                               97 (77--287)
  Total                                  415                                           14 549                                                                
                                                                                                                                                             
  *Autologous*                                                                                                                                              
   Low            \<25 HSCT per team     304                           48              3691                                18                               12 (1--25)
   Intermediate   25--75 HSCT per team   267                           43              11643                               55                               42 (26--74)
   High           \>75 HSCT per team     58                            9               5777                                27                               93 (76--227)
  Total                                  629                                           21 111                                                                

Abbreviation: HSCT=hematopoietic SCT.
